These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

711 related items for PubMed ID: 25847690

  • 1. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Verhagen Metman L, Stover N, Chen C, Cowles VE, Sweeney M.
    Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
    [Abstract] [Full Text] [Related]

  • 2. Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
    Warren Olanow C, Torti M, Kieburtz K, Leinonen M, Vacca L, Grassini P, Heller A, Heller E, Stocchi F.
    Mov Disord; 2019 Mar; 34(3):425-429. PubMed ID: 30653246
    [Abstract] [Full Text] [Related]

  • 3. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
    Hauser RA, Ellenbogen AL, Metman LV, Hsu A, O'Connell MJ, Modi NB, Yao HM, Kell SH, Gupta SK.
    Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
    [Abstract] [Full Text] [Related]

  • 4. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
    Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ.
    Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
    [Abstract] [Full Text] [Related]

  • 5. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
    Waters CH, Nausieda P, Dzyak L, Spiegel J, Rudzinska M, Silver DE, Tsurkalenko ES, Kell S, Hsu A, Khanna S, Gupta S.
    CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
    [Abstract] [Full Text] [Related]

  • 6. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
    Stocchi F, Hsu A, Khanna S, Ellenbogen A, Mahler A, Liang G, Dillmann U, Rubens R, Kell S, Gupta S.
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1335-40. PubMed ID: 25306200
    [Abstract] [Full Text] [Related]

  • 7. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease.
    Chen C, Cowles VE, Sweeney M, Stolyarov ID, Illarioshkin SN.
    Clin Neuropharmacol; 2012 Nov; 35(2):67-72. PubMed ID: 22377973
    [Abstract] [Full Text] [Related]

  • 9. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
    LeWitt PA, Huff FJ, Hauser RA, Chen D, Lissin D, Zomorodi K, Cundy KC.
    Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill®) in Parkinson's disease.
    LeWitt PA, Giladi N, Navon N.
    Parkinsonism Relat Disord; 2019 Aug; 65():131-138. PubMed ID: 31176632
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.
    LeWitt PA, Jennings D, Lyons KE, Pahwa R, Rabinowicz AL, Wang J, Guarnieri M, Hubble JP, Murck H.
    Mov Disord; 2009 Jul 15; 24(9):1319-24. PubMed ID: 19412946
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
    Chen C, Cowles VE, Sweeney M, Stolyarov ID, Illarioshkin SN.
    J Clin Pharmacol; 2012 Jul 15; 52(7):1069-77. PubMed ID: 21610205
    [Abstract] [Full Text] [Related]

  • 13. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
    Tetrud J, Nausieda P, Kreitzman D, Liang GS, Nieves A, Duker AP, Hauser RA, Farbman ES, Ellenbogen A, Hsu A, Kell S, Khanna S, Rubens R, Gupta S.
    J Neurol Sci; 2017 Feb 15; 373():116-123. PubMed ID: 28131167
    [Abstract] [Full Text] [Related]

  • 14. Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules.
    Modi NB, Mittur A, Rubens R, Khanna S, Gupta S.
    Clin Neuropharmacol; 2019 Feb 15; 42(1):4-8. PubMed ID: 30520758
    [Abstract] [Full Text] [Related]

  • 15. Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.
    Greig SL, McKeage K.
    CNS Drugs; 2016 Jan 15; 30(1):79-90. PubMed ID: 26692288
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK, Goetz CG, Leurgans S, Fan W, Nguyen T, Hsu A.
    Clin Neuropharmacol; 2009 Jan 15; 32(4):189-92. PubMed ID: 19620848
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations.
    Modi NB, Mittur A, Dinh P, Rubens R, Gupta S.
    Clin Neuropharmacol; 2019 Jan 15; 42(5):149-156. PubMed ID: 31306216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.